Theriva Biologics Inc TOVX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Theriva™ Biologics Announces Reverse Stock Split
Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results
Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc.
Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine
Trading Information
- Previous Close Price
- $0.13
- Day Range
- $0.12–0.14
- 52-Week Range
- $0.12–0.49
- Bid/Ask
- $0.09 / $0.10
- Shares Outstanding
- 45.89M
- Market Cap
- $5.51M
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 0.11
- Price/Sales
- 17.30
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 16
- Website
- https://www.therivabio.com
Valuation
Metric | TOVX |
|---|---|
Price/Earnings (Normalized) | 0.11 |
Price/Book Value | 0.55 |
Price/Sales | 17.30 |
Price/Cash Flow | — |
Price/Earnings
TOVX
Financial Strength
Metric | TOVX |
|---|---|
Quick Ratio | 1.17 |
Current Ratio | 1.21 |
Interest Coverage | — |
Quick Ratio
TOVX
Profitability
Metric | TOVX |
|---|---|
Return on Assets (Normalized) | −23.49% |
Return on Equity (Normalized) | −67.49% |
Return on Invested Capital (Normalized) | −55.27% |
Return on Assets
TOVX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|LMg^@&y | LOCK|@X>> | $132B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|s^&$f!& | LOCK|!J$?J | $96B | |||
| Moderna Inc MRNA | LOCK|Cxr?w@ | LOCK|gY | $81B | |||
| argenx SE ADR ARGX | LOCK|d@F^@!k | LOCK|<P | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|lGBJ@%L | LOCK|NC> | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|ZL!Hgh> | LOCK|sLT$ | $30B | |||
| Incyte Corp INCY | LOCK|fxmX>>x | LOCK|<! | $24B | |||
| BioNTech SE ADR BNTX | LOCK|!@pgYpJ | LOCK|PHh | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|cprv?J | LOCK|hr@Gk | $20B | |||
| BridgeBio Pharma Inc BBIO | LOCK|!lcp$!G | LOCK|&? | $15B |